FrancophonIA/ELRC3.0 huggingface dataset:
English: The naturally occurring human glucagon-like peptide-2 (GLP-2) is a peptide secreted by L cells of the intestine which is known to increase intestinal and portal blood flow, inhibit gastric acid secretion, and decrease intestinal motility.
Slovenian: Naravni človeški glukagonu podoben peptid-2 (GLP-2) je peptid, ki ga izločajo celice L v črevesu.
English: Use the 5 mg strength vial
Slovenian: >20 kg uporabljajte viale z jakostjo 5 mg
English: - After reconstitution, from a microbiological point of view, the solution should be used immediately.
Slovenian: - Z mikrobiološkega vidika je treba zdravilo uporabiti takoj po rekonstituciji.
English: Your doctor will perform further colonoscopies if you continue treatment with Revestive.
Slovenian: Če boste nadaljevali zdravljenje z zdravilom Revestive, vam bo zdravnik delal nadaljnje kolonoskopije.
English: If you are not sure, ask your doctor, pharmacist or nurse.
Slovenian: Če ste negotovi, se posvetujte s svojim z zdravnikom, farmacevtom ali medicinsko sestro.
English: Anxiety Insomnia
Slovenian: Psihiatrične motnje tesnoba nespečnost
English: Revestive 5 mg powder and solvent for solution for injection Teduglutide
Slovenian: Revestive 5 mg prašek in vehikel za raztopino za injiciranje teduglutid
English: How to store Revestive
Slovenian: Shranjevanje zdravila Revestive
English: Contact the doctor or the emergency unit if your child experiences severe stomach ache and fever - Intestinal obstruction (blockage of the bowel).
Slovenian: Posvetujte se z zdravnikom ali z urgentno enoto, če ima otrok hude bolečine v trebuhu, bruha in je zaprt.
English: Contact the doctor if your child experiences tiredness, shortness of breath or swelling of ankles or legs - Inflammation of the pancreas (pancreatitis).
Slovenian: Posvetujte se z zdravnikom, če vaš otrok občuti utrujenost, kratko sapo ali otekanje gležnjev ali nog.
English: Cholecystitis Cholecystitis acute
Slovenian: Bolezni jeter, žolčnika in žolčevodov holecistitis akutni holecistitis
English: CARTON
Slovenian: Vehikel
English: Contact your doctor or the emergency unit if you experience severe stomach ache and fever - Intestinal obstruction (blockage of the bowel).
Slovenian: Posvetujte se s svojim zdravnikom ali z urgentno enoto, če imate hude bolečine v trebuhu, bruhate in ste zaprti.
English: - Do not use Revestive if you notice that the solution is cloudy or contains particulate matter.
Slovenian: - Zdravila Revestive ne smete uporabiti, če je raztopina motna ali če vsebuje delce.
English: In case of recurrent intestinal obstructions, the need for continued Revestive treatment should be reassessed.
Slovenian: Če se zapore črevesa ponavljajo, je treba ponovno pretehtati potrebo po nadaljevanju zdravljenja z zdravilom Revestive.
English: Revestive 1.25 mg powder for solution for injection teduglutide
Slovenian: Revestive 1,25 mg prašek in vehikel za raztopino za injiciranje teduglutid subkutana uporaba
English: The recommended dose of Revestive is 0.05 mg/kg body weight once daily.
Slovenian: Priporočen odmerek zdravila Revestive je 0,05 mg/kg telesne mase enkrat na dan. Injicirani volumen na telesno maso je naveden v preglednici 1 v nadaljevanju.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING
Slovenian: Pripomočki, ki so na voljo v pakiranju:
English: Treatment should be initiated under the supervision of a medical professional with experience in the treatment of paediatric SBS.
Slovenian: Pediatrična populacija (≥1 leto) Zdravljenje se mora začeti pod nadzorom zdravnika, ki ima izkušnje z zdravljenjem SKČ pri otrocih.
English: SOLVENT PREFILLED SYRINGE LABEL
Slovenian: Žilne bolezni sinkopa
English: Hyperplasia in the gall bladder, hepatic biliary ducts, and pancreatic ducts were observed in subchronic and chronic toxicology studies.
Slovenian: V subkroničnih in kroničnih toksikoloških študijah so opazili hiperplazijo žolčnika, jetrnih žolčevodov in voda trebušne slinavke.
English: Pancreatitis Small intestinal stenosis
Slovenian: polipi (majhne nenormalne tvorbe) v želodcu.
English: One vial of powder contains 1.25 mg of teduglutide*.
Slovenian: KAKOVOSTNA IN KOLIČINSKA SESTAVA Ena viala praška vsebuje 1,25 mg teduglutida*.
English: Contact your doctor if you experience tiredness, shortness of breath or swelling of ankles or legs - Inflammation of the pancreas (pancreatitis).
Slovenian: Posvetujte se s svojim zdravnikom, če občutite utrujenost, kratko sapo ali otekanje gležnjev ali nog.
English: EU/1/12/787/002 1 vial EU/1/12/787/001 28 vials
Slovenian: ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET EU/1/12/787/003 28 vial
English: Revestive 5 mg powder for solution for injection teduglutide
Slovenian: Revestive 5 mg prašek in vehikel za raztopino za injiciranje teduglutid subkutana uporaba
English: Assemble the pre-filled syringe
Slovenian: Sestavite napolnjeno injekcijsko brizgo
English: Subcutaneous use vial (glass)
Slovenian: Velikost pakiranja subkutana ali intravenska uporaba intarvenska uporaba
English: The full EPAR for Zoledronic acid medac can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Zoledronska kislina medac je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It is available as a 4mg/100ml solution for infusion (drip into a vein) and as a 4mg/5ml concentrate for solution for infusion.
Slovenian: Na voljo je v obliki 4 mg/100 ml raztopine za infundiranje (kapalne infuzije v veno) in 4 mg/5 ml koncentrata za pripravo raztopine za infundiranje.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Zoledronic acid medac on 03 August 2012.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Zoledronska kislina medac, veljavno po vsej Evropski uniji, izdala 3. avgusta 2012.
English: For more information about treatment with Zoledronic acid medac, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Zoledronska kislina medac preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: This is a summary of the European public assessment report (EPAR) for Zoledronic acid medac.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Zoledronska kislina medac.
English: In addition, the company that markets Zoledronic acid medac will provide a card to inform patients about the risk of osteonecrosis of the jaw (damage to the bones of the jaw, which could lead to pain, sores in the mouth or loosening of teeth) and to instruct them to contact their doctor if they experience symptoms.
Slovenian: Poleg tega bo družba, ki trži zdravilo Zoledronska kislina medac pripravila izobraževalno kartico, s katero bo bolnike seznanila s tveganji osteonekroze čeljustnice (poškodbi čeljustne kosti, ki lahko povzroči bolečine, oteklost v ustih ali majanje zob) in jih pozvala, naj v primeru pojava simptomov poiščejo zdravniško pomoč.
English: The CHMP concluded that, in accordance with EU requirements, Zoledronic acid medac has been shown to have comparable quality and to be bioequivalent to Zometa.
Slovenian: CHMP je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Zoledronska kislina medac primerljivo raven kakovosti kot zdravilo Zometa ter da mu je biološko enakovredno.
English: Because Zoledronic acid medac is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Zoledronska kislina medac generično zdravilo in je biološko enakovredno referenčnemu zdravilu, so z njim povezane koristi in tveganja enaki kot pri referenčnem zdravilu.
English: This includes fractures (breaks in the bone), spinal compression (when the spinal cord is compressed by the bone), bone disorders needing radiotherapy (treatment with radiation) or surgery, and hypercalcaemia (high levels of calcium in the blood).
Slovenian: Ti zapleti so zlomi kosti, spinalna kompresija (ko hrbtenjačo stisne kost), kostna obolenja, ki zahtevajo radioterapijo (zdravljenje z obsevanjem) ali operacijo, ter hiperkalciemija (visoke ravni kalcija v krvi).
English: When used to prevent bone complications, the infusion can be repeated every three to four weeks, and patients should also take supplements of calcium and vitamin D. A lower dose is recommended for patients with bone metastases (when cancer has spread to the bone) if they have mild to moderate problems with their kidneys.
Slovenian: Pri uporabi za preprečevanje z okostjem povezanih zapletov se infundiranje lahko ponovi vsake tri do štiri tedne, bolniki pa morajo prejemati tudi dodatek kalcija in vitamina D. Pri bolnikih s kostnimi metastazami (rakom, ki se je razširil na kosti), ki imajo blage do zmerne težave z ledvicami, je priporočljiv nižji odmerek zdravila.
English: The usual dose of Zoledronic acid medac is one infusion of 4 mg over at least 15 minutes.
Slovenian: Običajni odmerek zdravila Zoledronska kislina medac je ena 4-miligramska infuzija v trajanju vsaj 15 minut.
English: This means that Zoledronic acid medac is similar to a ‘reference medicine' already authorised in the European Union (EU) called Zometa.
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Zometa.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Zoledronic acid medac, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: What measures are being taken to ensure the safe and effective use of Zoledronic acid medac?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Zoledronska kislina medac?
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Slovenian: Zmanjševanje izgubljanja kostnine vpliva na manjšo lomljivost kosti, kar je koristno pri preprečevanju zlomov pri bolnikih z rakom, z metastazami v kosteh.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid medac.
Slovenian: Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil zdravilo Zoledronska kilsina medac, na podlagi česar je oblikoval mnenje za odobritev dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
English: Zoledronic acid medac can be used to prevent bone complications in adults with advanced cancer that is affecting the bone.
Slovenian: Zdravilo Zoledronska kislina medac se lahko uporablja za preprečevanje z okostjem povezanih zapletov pri odraslih z napredovalim rakom, ki prizadene kosti.
English: What are the benefits and risks of Zoledronic acid medac?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Zoledronska kislina medac?
English: A risk management plan has been developed to ensure that Zoledronic acid medac is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Zoledronska kislina medac je bil pripravljen načrt obvladovanja tveganj.
English: Zoledronic acid medac must only be used by a doctor who has experience in the use of this type of medicine given into a vein.
Slovenian: Zdravilo Zoledronska kislina medac smejo uporabljati le zdravniki z izkušnjami z uporabo te vrste zdravil za intravensko uporabo.
English: Zoledronic acid medac can also be used to treat the hypercalcaemia caused by tumours.
Slovenian: Zdravilo Zoledronska kislina medac se lahko uporablja tudi za zdravljenje hiperkalciemije, ki jo povzročajo tumorji.
English: Therefore, the CHMP's view was that, as for Zometa, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi, tako kot pri zdravilu Zometa, odtehtajo znana tveganja.
English: Other information about Zoledronic acid medac
Slovenian: Druge informacije o zdravilu Zoledronska kislina medac
English: The Committee recommended that Zoledronic acid medac be given marketing authorisation.
Slovenian: Priporočil je, da se za zdravilo Zoledronska kislina medac izda dovoljenje za promet.
English: By preventing the breakdown of bones, Zoledronic acid medac also helps to reduce the amount of calcium released into the blood.
Slovenian: Zdravilo Zoledronska kislina medac s preprečevanjem razgradnje kosti pripomore tudi k znižanju ravni kalcija, ki se sprosti v kri.
English: Zoledronic acid medac is a ‘generic medicine'.
Slovenian: Zdravilo Zoledronska kislina medac je „generično zdravilo“.
English: Zoledronic acid medac is a medicine that contains the active substance zoledronic acid.
Slovenian: Zoledronska kislina medac je zdravilo, ki vsebuje zdravilno učinkovino zoledronska kislina.
English: Zoledronic acid medac zoledronic acid
Slovenian: Zoledronska kislina medac zoledronska kislina
English: The active substance in Zoledronic acid medac, zoledronic acid, is a bisphosphonate.
Slovenian: Zdravilna učinkovina zdravila Zoledronska kislina medac, zoledronska kislina, je difosfonat.
English: Why has Zoledronic acid medac been approved?
Slovenian: Zakaj je bilo zdravilo Zoledronska kislina medac odobreno?
English: No additional studies were needed as Zoledronic acid medac is a generic medicine that is given by infusion and contains the same active substance as the reference medicine, Zometa.
Slovenian: Ker je zdravilo Zoledronska kislina medac generično zdravilo, ki se daje z infundiranjem in vsebuje isto zdravilno učinkovino kot referenčno zdravilo Zometa, niso bile potrebne nobene dodatne študije.
English: How has Zoledronic acid medac been studied?
Slovenian: Kako je bilo zdravilo Zoledronska kislina medac raziskano?
English: How does Zoledronic acid medac work?
Slovenian: Kako zdravilo Zoledronska kislina medac deluje?
English: What is Zoledronic acid medac?
Slovenian: Kaj je zdravilo Zoledronska kislina medac?
English: What is Zoledronic acid medac used for?
Slovenian: Za kaj se zdravilo Zoledronska kislina medac uporablja?
English: How is Zoledronic acid medac used?
Slovenian: Kako se zdravilo Zoledronska kislina medac uporablja?
English: Further information on Sprycel can be found on the Agency's website ema.europa.eu/medicines/human/EPAR/Sprycel.
Slovenian: Nadaljnje informacije za zdravilo Sprycel so na voljo na spletni strani agencije ema.europa.eu/medicines/human/EPAR/Sprycel.
English: The dose is then gradually increased until the disease is controlled well enough.
Slovenian: Odmerek se nato postopoma povečuje, dokler ni bolezen zadovoljivo nadzorovana.
English: The doses for Sprycel tablets and suspension are not the same.
Slovenian: Odmerki za tablete in suspenzijo niso enaki.
English: It is taken once a day, consistently either in the morning or in the evening.
Slovenian: Zdravilo Sprycel se jemlje enkrat na dan, bodisi vedno zjutraj ali vedno zvečer.
English: The main measure of effectiveness was the proportion of patients who did not have an unwanted event within 3 years of treatment.
Slovenian: Glavno merilo učinkovitosti je bil delež bolnikov, ki niso imeli neželenega dogodka v treh letih zdravljenja.
English: Such events were: any sign of the disease in bone marrow, return of the disease anywhere in the body, a second cancer or death.
Slovenian: Tovrstni dogodki vključujejo: kakršen koli znak bolezni v kostnem mozgu, vrnitev bolezni kjer koli v telesu, drugi rak ali smrt.
English: What measures are being taken to ensure the safe and effective use of Sprycel?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Sprycel?
English: The European Medicines Agency decided that Sprycel's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je zaključila, da so koristi zdravila Sprycel večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: Sprycel is also used in children to treat:
Slovenian: Zdravilo Sprycel se uporablja tudi pri otrocih za zdravljenje:
English: What benefits of Sprycel have been shown in studies?
Slovenian: Kakšne koristi zdravila Sprycel so se pokazale v študijah?
English: Why is Sprycel authorised in the EU?
Slovenian: Zakaj je zdravilo Sprycel odobreno v EU?
English: What are the risks associated with Sprycel?
Slovenian: Kakšna tveganja so povezana z zdravilom Sprycel?
English: Other information about Sprycel
Slovenian: Druge informacije o zdravilu Sprycel
English: None of these studies compared Sprycel with another medicine.
Slovenian: V nobeni študiji niso zdravila Sprycel primerjali z drugim zdravilom.
English: Sprycel received a marketing authorisation valid throughout the European Union on 20 November
Slovenian: Za zdravilo Sprycel je bilo 20. novembra 2006 izdano dovoljenje za promet, veljavno po vsej EU.
English: An overview of Sprycel and why it is authorised in the EU
Slovenian: Pregled zdravila Sprycel in zakaj je odobreno v EU
English: As for all medicines, data on the use of Sprycel are continuously monitored.
Slovenian: Tako kot za vsako zdravilo se tudi podatki o uporabi zdravila Sprycel stalno spremljajo.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Sprycel have been included in the summary of product characteristics and the package leaflet.
Slovenian: Priporočila in previdnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Sprycel upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
English: Among patients treated with Sprycel and chemotherapy, 66% did not have an unwanted event.
Slovenian: Med bolniki, zdravljeni z zdravilom Sprycel in kemoterapijo, jih 66 % ni imelo neželenega dogodka.
English: The most common side effects with Sprycel (seen in more than 1 patient in 10) are infection, suppression of the bone marrow (decreasing numbers of blood cells), headache, haemorrhage (bleeding), pleural effusion (fluid around the lungs), dyspnoea (difficulty breathing), diarrhoea, vomiting, nausea (feeling sick), abdominal pain (belly ache), skin rash, musculoskeletal pain, tiredness, swelling in the legs and arms and in the face, fever.
Slovenian: Najpogostejši neželeni učinki zdravila Sprycel (opaženi pri več kot 1 bolniku od 10) so okužbe, supresija kostnega mozga (zmanjšano število krvnih celic), glavobol, hemoragija (krvavitev), plevralni izliv (tekočina v pljučih), dispneja (oteženo dihanje), driska, bruhanje, navzeja (siljenje na bruhanje), bolečine v trebuhu, kožni izpuščaj, mišično-skeletne bolečine, utrujenost, otekanje nog in rok ter obraza, povišana telesna temperatura.
English: What is Sprycel and what is it used for?
Slovenian: Kaj je zdravilo Sprycel in za kaj se uporablja?
English: The doctor may reduce the dose or interrupt treatment if blood cell counts are too low or certain side effects occur.
Slovenian: Zdravnik lahko zmanjša odmerek ali prekine zdravljenje, če je število krvnih celic prenizko ali če pride do nekaterih neželenih učinkov.
English: Sprycel is available as tablets (20, 50, 70, 80, 100 and 140 mg) and a powder to make up a suspension (10 mg/ml) to be taken by mouth.
Slovenian: Zdravilo Sprycel je na voljo v obliki tablet (20, 50, 70, 80, 100 in 140 mg) in praška za pripravo suspenzije (10 mg/ml) za peroralno uporabo.
English: Most of these studies assessed how well the leukaemia responded to treatment by measuring the levels of white cells and platelets in the blood, to see if they were returning to within normal levels, and by measuring the number of white blood cells that contained the Philadelphia chromosome, to see if it was decreasing.
Slovenian: V večini študij so ocenjevali, kako dobro se levkemija odziva na zdravljenje, z merjenjem ravni belih krvnih celic in trombocitov v krvi, da bi ugotovili, ali so se te vrnile na normalne ravni, in merjenjem deleža belih krvnih celic, ki vsebujejo kromosom Philadelphia, da bi ugotovili, ali se je ta znižal.
English: Side effects reported with Sprycel are carefully evaluated and any necessary action taken to protect patients.
Slovenian: Neželeni učinki, o katerih so poročali pri zdravilu Sprycel, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
English: The five main studies of Sprycel in adults involved 515 patients, all of whom had received treatment with imatinib, which had not worked or had stopped working.
Slovenian: V pet glavnih študij zdravila Sprycel pri odraslih je bilo vključenih 515 bolnikov, od katerih so se vsi zdravili z imatinibom, ki ni deloval ali je prenehal delovati.
English: Treatment is stopped if the medicine no longer controls the condition or if the patient cannot take the medicine because of side effects.
Slovenian: Zdravljenje se ustavi, če zdravilo ne nadzoruje več bolezni ali če bolnik ne more jemati zdravila zaradi neželenih učinkov.
English: For more information about using Sprycel, see the package leaflet or contact your doctor or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Sprycel glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
English: • newly diagnosed Ph+ ALL in combination with chemotherapy (cancer medicines).
Slovenian: • na novo diagnosticirane Ph+ ALL v kombinaciji s kemoterapijo (zdravili za zdravljenje raka).
English: The starting dose depends on the condition being treated and, for children, their body weight.
Slovenian: Začetni odmerek je odvisen od obravnavane bolezni in pri otrocih tudi telesne mase.
English: In comparison, using results of previous studies, the figure was 49% in patients who had received chemotherapy alone and 59% in patients who had received imatinib and chemotherapy.
Slovenian: V primerjavi z rezultati prejšnjih študij je bila ta številka 49 % pri bolnikih, ki so prejemali samo kemoterapijo, in 59 % pri bolnikih, ki so prejemali imatinib in kemoterapijo.
English: Sprycel was more effective than imatinib: within one year, 77% of patients receiving Sprycel no longer had the Philadelphia chromosome in their blood cells, compared with 66% of patients receiving imatinib.
Slovenian: Zdravilo Sprycel je bilo učinkovitejše od imatiniba: 77 % bolnikov, ki so prejemali zdravilo Sprycel, po enem letu v krvi ni več imelo kromosoma Philadelphia, v primerjavi s 66 % bolnikov, ki so prejemali imatinib.
English: The active substance in Sprycel, dasatinib, belongs to a group of medicines that block enzymes known as protein kinases.
Slovenian: Učinkovina zdravila Sprycel, dasatinib, spada v skupino zdravil, ki zavirajo encime, znane kot proteinske kinaze.
English: In addition, the number of white blood cells containing the Philadelphia chromosome was reduced in around 33 to 66% of treated patients in the five main studies.
Slovenian: Poleg tega se je v petih glavnih študijah število belih krvnih celic, ki vsebujejo kromosom Philadelphia, zmanjšalo pri približno 33 do 66 % zdravljenih bolnikov.
English: This enzyme is produced by leukaemia cells, and causes them to multiply uncontrollably.
Slovenian: Ta encim tvorijo levkemične celice, povzroča pa njihovo nenadzorovano razmnoževanje.
English: In a study involving 106 children and adolescents with newly diagnosed Ph+ ALL, patients were treated with Sprycel and chemotherapy.
Slovenian: V študiji, ki je vključevala 106 otrok in mladostnikov z na novo diagnosticirano Ph+ ALL, so bolniki prejemali zdravilo Sprycel in kemoterapijo.